Overview

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Nivolumab
Sargramostim
Vaccines